EMPA-REG OUTCOME: The Endocrinologist's Point of View

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention.

Colloquium on Therapy of Right Heart Failure

Kiran Sidhu, MD, FRCPC, Anthony Tang, MD, FRCPC

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Volume 56, Issue 1, Pages (July 1969)

Operative outcomes in mitral valve surgery: Combined effect of surgeon and hospital volume in a population-based analysis Arman Kilic, MD, Ashish S.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Manuel J. Antunes, MD, PhD, DSc

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Bacterial Infection and the Pathogenesis of COPD

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

OP-027 Aortic Distensibility in Postmenopausal Grandmultiparous Women with Metabolic Syndrome: A Comparison Between Revised NCEP ATP III and IDF Definitions.

PP-355 Endovascular Stenting Extension of Elephant Trunk Surgical Graft to Lower Descending Thoracic Aorta in a Patient with Aortic Arch and Descending.

Updates on CVOT Data and Clinical Comparisons That Matter

Bart Staels, PhD The American Journal of Medicine

Understanding EMPA-REG OUTCOME

Surgery for congenital diseases of the aorta

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Introduction The American Journal of Medicine

Understanding EMPA-REG OUTCOME

EMPA-REG OUTCOME: The Cardiologist's Point of View

ADA/EASD Position Statement: Approach to Hyperglycemia Management

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Can Vitamin D Deficiency Break Your Heart?

Philip E. Cryer, MD The American Journal of Medicine

Epidemiology of Myelodysplastic Syndromes

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update Mate Vamos, MD, PhD, Julia Wiebke Erath,

Antihyperglycemic Therapy

Understanding EMPA-REG OUTCOME

Centers for Disease Control “increased-risk” organ donor: Not so risky? Francis D. Pagani, MD, PhD The Journal of Thoracic and Cardiovascular Surgery

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Tetsuro Tsujimoto, Hiroshi Kajio International Journal of Cardiology

Form ever follows function

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

William M. DeCampli, MD, PhD

A new approach: Ischemic mitral regurgitation guidelines by and for surgeons Patrick M. McCarthy, MD The Journal of Thoracic and Cardiovascular Surgery

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Aamir Jeewa, MD, Cedric Manlhiot, BS, Paul F

Bigger The Journal of Thoracic and Cardiovascular Surgery

Predictors of 90-day mortality after congenital heart surgery: The first report of risk models from a Japanese database Hiroaki Miyata, PhD, Arata Murakami,

Impact of prior hospital mortality versus surgical volume on mortality following surgery for congenital heart disease Matthew E. Oster, MD, Matthew J.

John R. Petrie, MD, PhD, Tomasz J. Guzik, MD, PhD, Rhian M

Polyunsaturated Fatty Acids and Kidney Disease

Support Your Specialty

The assessment of cost effectiveness and the effectiveness of cost assessment in cardiothoracic surgery Vinay Badhwar, MD The Journal of Thoracic and.

It's not “just a shunt” but sometimes it should be…

Mitotic Inhibitors Journal of Thoracic Oncology

Insomnia in the Elderly: Cause, Approach, and Treatment

A fate worse than death Jennifer S. Lawton, MD

Long-term Outcomes of Acute Kidney Injury: The Power and Pitfalls of Observational/Population-Based Studies Charuhas V. Thakar, MD American Journal.

Passing the torch The Journal of Thoracic and Cardiovascular Surgery

Functional tricuspid pathology: To treat or not to treat

The harder one looks, the more one finds

The origins of open heart surgery at the University of Minnesota 1951 to 1956 Richard A. DeWall, MD The Journal of Thoracic and Cardiovascular Surgery

EFFECTS OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS ON MORTALITY, CARDIOVASCULAR HOSPITALIZATION AND FUNCTIONAL CAPACITY IN PATIENTS WITH HEART.

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

KEYNOTE-024: Unlocking a pathway to lung cancer cure?

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Direct Observation of Residents: A Model for an Assessment System

Building a clinical program in a single institution

“The more things change…”: The challenges ahead

Ryan R. Davies, MD The Journal of Thoracic and Cardiovascular Surgery

Respect the aorta The Journal of Thoracic and Cardiovascular Surgery

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

Figure 1 ABCDE of primary prevention.2

Surgery for secondary tricuspid regurgitation: Rings, bands, or sutures, does it matter? Manuel J. Antunes, MD The Journal of Thoracic and Cardiovascular.

Calpain inhibitors: The aspirin of the 21st century?

Presentation transcript:

EMPA-REG OUTCOME: The Endocrinologist's Point of View Leigh Perreault, MD American Journal of Cardiology Volume 120, Issue 1, Pages S48-S52 (July 2017) DOI: 10.1016/j.amjcard.2017.05.010 Copyright © 2017 The Author Terms and Conditions

Figure 1 Schematic representation of the potential metabolic and hemodynamic pathways responsible for the reduction in mortality and hospitalization for heart failure observed with empagliflozin in EMPA-REG OUTCOME.19 American Diabetes Association “SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.” American Diabetes Association, 2016 Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association. Ang 1-7 = angiotensin 1-7; AT2 = angiotensin 2 receptor; ECFV = extracellular fluid volume; FFA = free fatty acids. American Journal of Cardiology 2017 120, S48-S52DOI: (10.1016/j.amjcard.2017.05.010) Copyright © 2017 The Author Terms and Conditions